-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NTAggzIms+O1IF+BF/pgM/6Q3Bu4vAx3PTNHVwwInTB9GzPcivXYDAgT3AMdIvIO sKCxm8kgcd+BgKoTIILM5Q== 0001017062-02-001545.txt : 20020814 0001017062-02-001545.hdr.sgml : 20020814 20020814141201 ACCESSION NUMBER: 0001017062-02-001545 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020814 ITEM INFORMATION: FILED AS OF DATE: 20020814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WATSON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884629 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 953872914 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13305 FILM NUMBER: 02734470 BUSINESS ADDRESS: STREET 1: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 92880 BUSINESS PHONE: 9092701400 MAIL ADDRESS: STREET 1: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 92880 8-K 1 d8k.htm FORM 8-K Prepared by R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant To Section 13 or 15(d) Of the Securities And Exchange Act Of 1934
 
August 14, 2002
Date of Report (Date of earliest event reported)
 
 
WATSON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
 
Nevada
     
0-20045
     
95-3872914
(State or other Jurisdiction of
Incorporation)
     
(Commission File Number)
     
(IRS Employer Identification Number)
311 Bonnie Circle
Corona, California
(Address of principal executive offices)
            
92880
(Zip Code)
 
(909) 493-5300
(Registrant’s telephone number, including area code)
 
N/A
(Former Name or Former Address, if Changed Since Last Report)
 

 
Item 9.    Regulation FD Disclosure.
 
On August 14, 2002, the Registrant filed its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2002 (the “Form 10-Q”) with the Securities and Exchange Commission. In connection with the filing of the Form 10-Q, the Registrant has provided to the Securities and Exchange Commission the certifications below, as required by 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002:
 
Certification of Chief Executive Officer
 
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Watson Pharmaceuticals, Inc. (the “Company”), hereby certifies, to such officer’s knowledge, that:
 
(i)  the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2002 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
(ii)  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: August 14, 2002
/s/    ALLEN CHAO, PH.D.            
Allen Chao, Ph.D.
President and Chief Executive Officer
 
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
Certification of Chief Financial Officer
 
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Watson Pharmaceuticals, Inc. (the “Company”), hereby certifies, to such officer’s knowledge, that:
 
(i)  the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2002 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
(ii)  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: August 14, 2002
/s/    MICHAEL E. BOXER            
Michael E. Boxer
Senior Vice President and Chief Financial Officer
 
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 

2

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Dated: August 14, 2002.
WATSON PHARMACEUTICALS, INC.
 
By:
  
/s/    MICHAEL E. BOXER         
   
Michael E. Boxer
Senior Vice President and Chief Financial Officer
-----END PRIVACY-ENHANCED MESSAGE-----